Tag: incretin
-
Retatrutide in early type 2 diabetes — the glucose axis converges, the weight axis does not
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In 537 adults with early type 2 diabetes inadequately controlled on diet and exercise (mean duration 2.5 years, HbA1c 7.9%, BMI 35.8), 40 weeks of once-weekly…
-
The next-generation obesity pipeline: from “how much you lose” to “at what cost”
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The next-generation obesity drugs push weight-loss efficacy along three vectors: triple agonists (retatrutide), oral small molecules (orforglipron), and amylin combinations (CagriSema). At the top end, retatrutide’s…
-
Making the molecule — the real rate-limiting step behind the GLP-1 headline is manufacturing physics, not efficacy
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The headline for the GLP-1 class is efficacy (about −20% weight, about −20% cardiovascular events). But the real rate-limiting step for population-level access is manufacturing physics:…
-
The next-generation obesity pipeline: from “how much you lose” to “at what cost”
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → The next-generation obesity pipeline, and why the competitive question is shifting from how much weight a drug removes to what that removal costs in lean mass, tolerability…
-
The GLP-1 / incretin landscape — why the question moved from “how much weight?” to “what does it change?”
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The incretin (GLP-1) class is expanding beyond glucose and weight into cardiovascular, kidney and heart-failure indications. In the only two head-to-head trials, the dual agent (tirzepatide)…
Uthando Nethemba 